New Full-Body scan could replace biopsies for breast cancer immunotherapy
NCT ID NCT05742269
First seen Mar 15, 2026 · Last updated Jun 20, 2026 · Updated 16 times
Summary
This study tested a special PET/CT scan that uses a radioactive tracer to visualize PD-L1, a protein targeted by immunotherapy, throughout the body. The goal was to see if this scan could better identify which patients with metastatic triple-negative breast cancer would benefit from treatment, compared to the standard biopsy method. Only 3 participants were enrolled before the study was terminated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Karolinska University Hospital
Stockholm, 171 76, Sweden
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-atezolizumab (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this imaging method could help doctors choose the right immunotherapy for breast cancer patients without needing a biopsy.
What could go wrong
This was a very small, early study (only 3 participants planned) and was terminated, so results are limited. The method may not prove better than current tests.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.